Online inquiry

IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3990MR)

This product GTTS-WQ3990MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LTB&TNFSF14 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002341.2; NM_003807.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4050; 8740
UniProt ID Q06643; O43557
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3990MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2582MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ9312MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ5147MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ656MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ9097MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ11631MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ8582MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ12697MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-21M18
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW